Table 2.

Selected clinical trials for CAR-NK cells in solid and haematological malignancies from www.clinicaltrials.gov

Disease setting	Target antigen	Cellular source	Clinical phase	Clinical trial number	Status	Sponsor
Advanced solid tumours	Claudin6	Autologous PBMC	Phase I/II	NCT05410717	Recruiting	Second Affiliated Hospital of Guangzhou Medical University
Relapsed or refractory haematological malignancies	CD70	Cord blood	Phase I/II	NCT05092451	Recruiting	M.D. Anderson Cancer Center
Relapsed or refractory B-cell non-Hodgkin lymphoma	CD19	Cord blood	Phase II	NCT05020015	Recruiting	Takeda
Recurrent/metastatic gastric or head and neck cancer	PD-L1	Engineered NK-92 cells	Phase II	NCT04847466	Recruiting	National Cancer Institute
Relapsed or refractory B-cell lymphoma or chronic lymphocytic leukemia	CD19	iPSC	Phase I	NCT04245722	Active, not recruiting	Fate Therapeutics
Relapsed or refractory multiple myeloma	BCMA	iPSC	Phase I	NCT05182073	Recruiting	Fate Therapeutics
Acute myeloid leukaemia	CD33/ CLL1	Information not available	Phase I	NCT05215015	Recruiting	Wuxi People’s Hospital
Relapsed and refractory multiple myeloma	BCMA	NK92	Phase I/II	NCT03940833	Unknown	Asclepius Technology Company Group (Suzhou) Co., Ltd.
Recurrent HER2-positive glioblastoma	HER2	NK-92/5.28.z	Phase I	NCT03383978	Recruiting	Johann Wolfgang Goethe University Hospital
Relapsed or refractory CD19-positive B-cell malignancies	CD19	iPSC	Phase I	NCT05336409	Recruiting	Century Therapeutics, Inc.
Recurrent or refractory CD19 positive B-cell malignant tumours	CD19	Information not available	Phase I	NCT05410041	Recruiting	Beijing Boren Hospital
MUC1 positive advanced refractory or relapsed solid tumours	MUC1	Information not available	Phase I/II	NCT02839954	Unknown	PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Locally advanced or metastatic pancreatic cancer	PD-L1	Engineered NK-92 cells	Phase II	NCT04390399	Recruiting	ImmunityBio, Inc.
Patients who have previously received treatment with PD-1/PD-L1 immune checkpoint inhibitors	PD-L1	Engineered NK-92 cells	Phase II	NCT03228667	Active, not recruiting	ImmunityBio, Inc.